Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

Last Friday, the three most widely followed benchmark indexes closed a losing week. The Nasdaq Composite, the S&P 500 and the ...

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Amgen Inc. urged a federal judge to overturn a jury’s $50.3 million verdict for its leukemia drug Blincyto’s infringement of ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

A federal judge has dismissed Amgen’s lawsuit against Colorado’s Prescription Drug Affordability Board, allowing the state to move forward with setting price ceilings on prescription drugs, The Denver ...